Hybio Pharmaceutical (300199) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.177x

Based on the latest financial reports, Hybio Pharmaceutical (300199) has a cash flow conversion efficiency ratio of 0.177x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥117.78 Million ≈ $17.23 Million USD) by net assets (CN¥666.08 Million ≈ $97.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300199 equity financing ratio to measure how much of total assets are equity-financed.

Hybio Pharmaceutical - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Hybio Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Hybio Pharmaceutical to evaluate the quality of earnings relative to operating cash generation.

Hybio Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hybio Pharmaceutical ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Lerøy Seafood Group ASA OL:LSG	0.188x
China Suntien Green Energy Corp Ltd SHG:600956	0.093x
Acer Incorporated F:AC5G	0.017x
CECEP Solar Energy Co Ltd SHE:000591	0.112x
Shenzhen Kstar Science & Technology Co Ltd SHE:002518	0.079x
Shanghai Tunnel Engineering Co Ltd SHG:600820	0.135x
Shanghai Jin Jiang International Hotels Development Co Ltd A SHG:600754	0.091x
CorporaciÃ³n Inmobiliaria Vesta, S.A.B de C.V. NYSE:VTMX	0.019x

Annual Cash Flow Conversion Efficiency for Hybio Pharmaceutical (2007–2024)

The table below shows the annual cash flow conversion efficiency of Hybio Pharmaceutical from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see Hybio Pharmaceutical market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥597.05 Million ≈ $87.37 Million	CN¥164.71 Million ≈ $24.10 Million	0.276x	+6209.36%
2023-12-31	CN¥783.21 Million ≈ $114.61 Million	CN¥-3.54 Million ≈ $-517.51K	-0.005x	-137.05%
2022-12-31	CN¥1.30 Billion ≈ $189.78 Million	CN¥15.81 Million ≈ $2.31 Million	0.012x	-87.19%
2021-12-31	CN¥1.65 Billion ≈ $241.15 Million	CN¥156.83 Million ≈ $22.95 Million	0.095x	+232.72%
2020-12-31	CN¥1.68 Billion ≈ $245.53 Million	CN¥47.99 Million ≈ $7.02 Million	0.029x	-38.96%
2019-12-31	CN¥2.23 Billion ≈ $326.77 Million	CN¥104.64 Million ≈ $15.31 Million	0.047x	+238.15%
2018-12-31	CN¥3.39 Billion ≈ $496.31 Million	CN¥47.00 Million ≈ $6.88 Million	0.014x	-74.81%
2017-12-31	CN¥3.88 Billion ≈ $568.47 Million	CN¥213.74 Million ≈ $31.28 Million	0.055x	-33.09%
2016-12-31	CN¥3.60 Billion ≈ $527.46 Million	CN¥296.41 Million ≈ $43.37 Million	0.082x	+56.20%
2015-12-31	CN¥2.64 Billion ≈ $385.92 Million	CN¥138.84 Million ≈ $20.32 Million	0.053x	-55.53%
2014-12-31	CN¥1.30 Billion ≈ $189.67 Million	CN¥153.43 Million ≈ $22.45 Million	0.118x	-13.29%
2013-12-31	CN¥1.12 Billion ≈ $164.51 Million	CN¥153.48 Million ≈ $22.46 Million	0.137x	+59.09%
2012-12-31	CN¥1.02 Billion ≈ $148.68 Million	CN¥87.19 Million ≈ $12.76 Million	0.086x	+15.57%
2011-12-31	CN¥976.09 Million ≈ $142.83 Million	CN¥72.48 Million ≈ $10.61 Million	0.074x	-75.48%
2010-12-31	CN¥180.59 Million ≈ $26.43 Million	CN¥54.69 Million ≈ $8.00 Million	0.303x	+48.18%
2009-12-31	CN¥127.74 Million ≈ $18.69 Million	CN¥26.11 Million ≈ $3.82 Million	0.204x	-55.67%
2008-12-31	CN¥99.23 Million ≈ $14.52 Million	CN¥45.75 Million ≈ $6.69 Million	0.461x	-54.21%
2007-12-31	CN¥48.70 Million ≈ $7.13 Million	CN¥49.04 Million ≈ $7.18 Million	1.007x	--

About Hybio Pharmaceutical

SHE:300199 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.64 Billion

CN¥18.05 Billion CNY

Market Cap Rank

#5228 Global

#897 in China

Share Price

CN¥20.44

Change (1 day)

-3.13%

52-Week Range

CN¥16.36 - CN¥29.95

All Time High

CN¥29.95